KMT2A and leukemia: Importantly, reduced c-MYB levels are still compatible with normal hematopoiesis, therefore inhibition of c-MYB appears to have a therapeutic opportunity for MLL-rearranged leukemia (Emambokus et al., 2003; Zuber et al., 2011).